April 27, 2023 – One of the most highly-anticipated events at the ATS 2023 International Conference, which kicks off May 19, is the “Breaking News: Clinical Trial Results in Pulmonary Medicine.” Taking place on Monday, May 22, the series of presentations will focus on the latest regarding COPD and asthma treatment.
Register now to hear these presentations live. A question-and-answer period will follow all presentations:
- Seralutinib Treatment in Adult Subjects with Pulmonary Arterial Hypertension: Results from the TORREY Study
- Effect of Ensifentrine, a Novel PDE3 and PDE4 Inhibitor, on Lung Function, Symptoms and Exacerbations in Patients with COPD: The Enhance Trials
- Targeting of TSLP and IL-13 by the Novel NANOBODY Molecule SAR443765 Reduces FeNO in Asthma Following Single Dose Exposure
- Efficacy and Safety of Dupilumab in Chronic Obstructive Pulmonary Disease with Type 2 Inflammation
For more asthma research sessions, visit our conference site here. See all COPD research presentations here.
Media registration is available now as well as on-site in DC. We encourage advanced registration to fast-track your conference news coverage.
Share via Twitter: Latest treatment for #COPD and #asthma highlight of Clinical Trial session at #ATS2023 in Washington, DC. https://bit.ly/3Ne9lna
MEDIA CONTACT
Register for reporter access to contact detailsCITATIONS
ATS 2023 International Conference
RSS